Eptifibatide is a GPIIb/IIIa inhibitor. It is filed in this library under heart & blood, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Eptifibatide has an FDA-approved product on the U.S. market, marketed as Eptifibatide under application ANDA206127.
The current label is held by Eugia US LLC.
From the FDA label
ptifibatide injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) Treatment of patients undergoing PCI (including intracoronary stenting) 1.1 Acute Coronary Syndrome (ACS) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI).Quoted from the FDA-approved prescribing information
The evidence
2 sources on Eptifibatide published between 1991 and 1998, each resolved to its journal of record. Titles are listed so you can judge the evidence rather than take a summary on trust.
Nearby
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Eptifibatide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides